The safety of current pharmacotherapeutic strategies for osteosarcoma

References

• Stiller CA, Trama A, Serraino D. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–695.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36:188‐193.
   Web of Science ®Google Scholar
• Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO–paedcan–EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement 4):iv79–iv95.
   PubMedGoogle Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23: 2004–2011.
   Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449–453.
   PubMed Web of Science ®Google Scholar
• Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2003;21: 2011–2018.
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314::1600–1606.
   PubMed Web of Science ®Google Scholar
• Bramer JA, van Linge JH, Grimer RJ, et al. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol. 2009;35:1030–1036.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12:2699–2705.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Onco. 2015;26(2):407–414.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426–433.
   PubMed Web of Science ®Google Scholar
• Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22:441–445.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–464.
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010 November:2(11): 2490–2518. Epub 2010 Oct 26..
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999;83:866–869.
   PubMed Web of Science ®Google Scholar
• Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25:47–58.
   PubMed Web of Science ®Google Scholar
• Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Ped Blood Cancer. 2007;48:140–147.
   PubMed Web of Science ®Google Scholar
• Koch Nogueira PC, Hadj-Aissa A, Schell M, et al. Long-term nephrotoxicity of cisplatin, IFO, and MTX in osteosarcoma. Ped Nephrol. 1998;12::572–575.
   PubMed Web of Science ®Google Scholar
• Santoso JT, Lucci JA III, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother Pharmacol. 2003;52:13–18.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Nazneen A, Abid MR, et al. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol. 2005;148:107–121.
   PubMed Web of Science ®Google Scholar
• Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65:307–314.
   PubMed Web of Science ®Google Scholar
• de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol. [2001 September 1];19(17):3733–3739.
   PubMed Web of Science ®Google Scholar
• de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003 April 22;88(8):1199–1206.
   PubMed Web of Science ®Google Scholar
• Raj GV, Iasonos A, Herr H, et al. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006 July 1;24(19):3095–3100.
   PubMed Web of Science ®Google Scholar
• Scott LA, Madan E, Valentovic MA. Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. Fundam Appl Toxicol. 1989 April;12(3):530–539.
   PubMedGoogle Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009 October;86(4):396–402.
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010 March;176(3):1169–1180.
   PubMed Web of Science ®Google Scholar
• Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with IFO and cisplatin in patients with osteogenic sarcoma. Med Ped Oncol. 1999;32:93–96.
   PubMedGoogle Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 October;17(10):1396–1408.
   PubMed Web of Science ®Google Scholar
• Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer. 1998;77:1677–1682.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemo Pharmacol. 2008;61:903–909.
   PubMed Web of Science ®Google Scholar
• Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993 August;50(2):147–158.
   PubMed Web of Science ®Google Scholar
• Lehane D, Winston A, Gray R, et al. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys. 1979 August;5(8):1393–1399.
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep. [1982 January];66(1):31–35.
   PubMedGoogle Scholar
• Skinner R, Sharkey IM, Pearson AD, et al. IFO, mesna, and nephrotoxicity in children. J Clin Oncol. 1993;11:173–190.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lu H. IFO induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic Biol Med. 2007;43:1574–1583.
   PubMed Web of Science ®Google Scholar
• Nissim I, Horyn O, Daikhin Y, et al. IFO-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006;66:7824–7831.
   PubMed Web of Science ®Google Scholar
• Loebstein R, Koren G. IFO-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998;101:E8.
   PubMed Web of Science ®Google Scholar
• Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of IFO-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12:159–165.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Meyer WH, Jenkins JJ, et al. IFO, Fanconi’s syndrome, and rickets. J Clin Oncol. 1991;9(8):1495–1499.
   Google Scholar
• Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 1996;348(9027):578–580.
   Web of Science ®Google Scholar
• Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after IFO treatment in children: a UKCCSG late effects group study. United Kingdom children’s cancer study group. Br J Cancer. 2000;82:1636–1645.
   PubMed Web of Science ®Google Scholar
• Aleksa K, Woodland C, Koren G. Young age and the risk for IFO-induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol. 2001;16:1153–1158.
   PubMed Web of Science ®Google Scholar
• Bleyer WA. MTX: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4:87–101.
   PubMed Web of Science ®Google Scholar
• Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent MTX toxicity. N Engl J Med. 1977;297:630–634.
   PubMed Web of Science ®Google Scholar
• Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983;1(3):208–216.
   Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose MTX-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100(10):2222–2232.
   Web of Science ®Google Scholar
• Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet. 1986;11:223–235.
   PubMed Web of Science ®Google Scholar
• Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol. 2009;5(8):450–462.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with MTX-induced renal dysfunction. J Clin Oncol. 1997;15:2125–2134.
   PubMed Web of Science ®Google Scholar
• Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with MTX intoxication and renal failure. Br J Cancer. 2005;92:480–487.
   PubMed Web of Science ®Google Scholar
• Fleming RA. An overview of cyclophosphamide and IFO pharmacology. Pharmacotherapy. 1997;17 ( 146Se154S).
   PubMed Web of Science ®Google Scholar
• Frisk P, Stalberg E, Stromberg B, et al. Painful peripheral neuropathy after treatment with high-dose IFO. Med Pediatr Oncol. 2001;37:379–382.
   PubMedGoogle Scholar
• Pinkerton CR, Rogers H, James C, et al. A phase II study of IFO in children with recurrent solid tumours. Cancer Chemother Pharmacol. 1985;15:258–262.
   PubMed Web of Science ®Google Scholar
• Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of IFO encephalopathy. Eur J Clin Pharmacol. 1996;50:249–252.
   PubMed Web of Science ®Google Scholar
• Chatton JY, Idle JR, Vagbo CB, et al. Insights into the mechanisms of IFO encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther. 2001;299:1161–1168.
   PubMed Web of Science ®Google Scholar
• Van Dyk JJ, Falkson HC, Van der Merwe AM, et al. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972;32:921–924.
   PubMed Web of Science ®Google Scholar
• Sparr SA. Experimental and Clinical Neurotoxicology, , ed 2 ed. New York: Oxford University Press, 2000:675–677. IFO; in Spencer PS, Schaumburg HH (eds).
   Google Scholar
• Meanwell CA, Blake AE, Latief TN, et al. Encephalopathy associated with ifosphamide/mesna therapy. Lancet. 1985;1(8425):406–407.
   PubMed Web of Science ®Google Scholar
• Bremner DN, McCormick JS. Thomson JW: clinical trial of isophosphamide (NSC- 109724) – results and side effects. Cancer Chemother Rep. 1974;58:889–893.
   PubMedGoogle Scholar
• Salloum E, Flamant F, Ghosn M, et al. Akatchereian C: irreversible encephalopathy with IFO/mesna. J Clin Oncol. 1987;5:1303–1304.
   PubMed Web of Science ®Google Scholar
• Merimsky O, Reider-Groswasser I, Wigler N, et al. Encephalopathy in IFO treated patients. Acta Neurol Scand. 1992;86:21–525.
   Web of Science ®Google Scholar
• DiMaggio JR, Brown R, Baile WF, et al. IFO-induced neurotoxicity. Cancer. 1994;73:1509–1514.
   PubMed Web of Science ®Google Scholar
• Nelson RL, Creaven PJ, Cohen MH, et al. Phase I clinical trial of a 3-day divided dose schedule of IFO (NSC 109724). Eur J Cancer. 1976;12:195–198.
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Bodey GP, Freireich EJ, et al. Reduction of IFO toxicity using dose fractionation. Cancer Res. 1976;36:2945–2948.
   PubMed Web of Science ®Google Scholar
• Klein HO, Wickramanayake PD, Coerper C, et al. High-dose IFO and mesna as continuous infusion over five days – A phase I/II trial. Cancer Treat Rev. 1983;10:167–173, suppl A
   PubMed Web of Science ®Google Scholar
• Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of IFO in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131–135.
   PubMedGoogle Scholar
• Perren TJ, Turner RC, Smith IE. Encephalopathy with rapid infusion IFO/mesna. Lancet. 1987;390–391. i.
   PubMed Web of Science ®Google Scholar
• David KA, Picus J. Evaluating risk factors for the development of IFO encephalopathy. Am J Clin Oncol. 2005;28:277e280.
   Web of Science ®Google Scholar
• Anderson NR. Tandon DS: IFO extrapyramidal neurotoxicity. Cancer. 1991;68:72–75.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Hoffman PC. CNS Toxicity during IFO-Based Chemotherapy. Princeton: Bristol-Meyers Squibb Co; 1996.
   Google Scholar
• Meyer T, Ludolph AC, Munch C. IFO encephalopathy presenting with asterixis. J Neurol Sci. 2002;199:85–88.
   PubMed Web of Science ®Google Scholar
• Wengs WJ, Talwar D, Bernard J. IFO-induced nonconvulsive status epilepticus. Arch Neurol. 1993;50:1104–1105.
   PubMedGoogle Scholar
• Primavera A, Audenino D, Cocito L. IFO encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci. 2002;29:180–183.
   PubMed Web of Science ®Google Scholar
• Anderson NR, Tandon DS. IFO extrapyramidal neurotoxicity. Cancer. 1991;68:72–75.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with IFO/mesna. J Clin Oncol. 1986;4:1253–1261.
   PubMed Web of Science ®Google Scholar
• Meanwell CA, Blake AE, Kelly KA, et al. Prediction of IFO/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986;22:815–819.
   PubMedGoogle Scholar
• Simonian NA, Gilliam FG, Chiappa KH. IFO causes a diazepam-sensitive encephalopathy. Neurology. 1993;43:2700–2702.
   PubMed Web of Science ®Google Scholar
• Gieron MA, Barak LS, Estrada J. Severe encephalopathy associated with IFO administration in two children with metastatic tumors. J Neurooncol. 1988;6:29–30.
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Photopulos G, et al. Gynecologic oncology group experience with IFO. Semin Oncol. 1990;17(suppl 4):6–10.
   PubMedGoogle Scholar
• Cantwell BM, Idle M, Millward MJ, et al. Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous IFO infusion. Ann Oncol. 1990;1:232.
   PubMed Web of Science ®Google Scholar
• Antman KH, Elias A, IF RL. O and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990;17(suppl 4):68–73.
   PubMedGoogle Scholar
• Watkin SW, Husband DJ, Green JA, et al. IFO encephalopathy: a reappraisal. Eur J Cancer Clin Oncol. 1989;25:1303–1310.
   PubMedGoogle Scholar
• Meanwell CA, Kelly KA, Blackledge G. Avoiding IFO/mesna encephalopathy. Lancet. 1986;2:406.
   PubMed Web of Science ®Google Scholar
• McCallum AK. IFO/mesna encephalopathy. Lancet. 1987;1:987.
   PubMed Web of Science ®Google Scholar
• Ghosn M, Carde P, Leclerq B, et al. IFO/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer. 1988;75:391–392.
   PubMed Web of Science ®Google Scholar
• Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of IFO-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–294.
   PubMed Web of Science ®Google Scholar
• McVay JI, Wood AM, Suspected IF. O-induced neurotoxicity. Pharmacotherapy. 1999;19:1450–1455.
   PubMed Web of Science ®Google Scholar
• Kasper B, Harter C, Meer J, et al. Prophylactic treatment of known IFO-induced encephalopathy for chemotherapy with high-dose IFO? Support Care Cancer. 2004;12:205–207.
   PubMed Web of Science ®Google Scholar
• Raj AB, Bertolone SJ, Jaffe N. Methylene blue reversal of IFO-related encephalopathy. J Pediatr Hematol Oncol. 2004;26:116.
   PubMed Web of Science ®Google Scholar
• Visarius TM, Bahler H, Kupfer A, et al. Thiodiglycolic acid is excreted by humans receiving IFO and inhibits mitochondrial function in rats. Drug Metab Dispos. 1998;26:193–196.
   PubMed Web of Science ®Google Scholar
• Kupfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of IFO encephalopathy with methylene blue. Lancet. 1994;343:763–764.
   PubMed Web of Science ®Google Scholar
• Harpey JP, Charpentier C, Coude M. Methylene blue for riboflavin-unresponsive glutaric aciduria type II. Lancet. 1986;1(8477):391.
   Web of Science ®Google Scholar
• Sul JK, Deangelis LM. Neurologic complications of cancer chemotherapy. Semin Oncol. 2006;33(3):324–332.
   PubMed Web of Science ®Google Scholar
• Shuper A, Stark B, Kornreich L, et al. MTX related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J. 2002;4(11):1050–1053.
   PubMed Web of Science ®Google Scholar
• Shao Y, Tan B, Shi J, et al. MTX induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system. Toxicol Lett. 2019;301:146–156.
   PubMed Web of Science ®Google Scholar
• Rollins N, Winick N, Bash R, et al. Acute MTX neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol. 2004;25(10):1688–1695.
   PubMed Web of Science ®Google Scholar
• Celik F, Gocmez C, Bozkurt M, et al. Neuroprotective effects of carvacrol and pomegranate against MTX-induced toxicity in rats. Eur Rev Med Pharmacol Sci. 2013;17(22):2988–2993.
   PubMed Web of Science ®Google Scholar
• Taylor OA, Hockenberry MJ, McCarthy K, et al. Evaluation of biomarkers of oxidative stress and apoptosis in patients with severe MTX neurotoxicity: a case series. J Pediatr Oncol Nurs. 2015;32(5):320–325.
   PubMed Web of Science ®Google Scholar
• Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084–3091.
   PubMed Web of Science ®Google Scholar
• Jaffe N, Takaue Y, Anzai T, et al. Transient neurologic disturbances induced by high-dose MTX treatment. Cancer. 1985;56:1356–1360.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sabin ND, Pei D, et al. MTX induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–959.
   PubMed Web of Science ®Google Scholar
• Walker RW, Allen JC, Rosen G, et al. Transient cerebral dysfunction secondary to high-dose MTX. J Clin Oncol. 1986;4:1845–1850.
   PubMed Web of Science ®Google Scholar
• Inaba H, Khan RB, Laningham FH, et al. Clinical and radiological characteristics of MTX-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178–184.
   PubMed Web of Science ®Google Scholar
• Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute MTX neurotoxicity. Ped Hematol Oncol. 2002;19:319–327.
   PubMed Web of Science ®Google Scholar
• Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet. 1995;345:544–547.
   PubMed Web of Science ®Google Scholar
• Uzar E, Koyuncuoglu HR, Uz E, et al. The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to MTX: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem. 2006;291(1–2):63–68.
   PubMed Web of Science ®Google Scholar
• Vardi N, Parlakpinar H, Ates B. Beneficial effects of chlorogenic acid on MTX-induced cerebellar Purkinje cell damage in rats. J Chem Neuroanat. 2012;43(1):43–47.
   PubMed Web of Science ®Google Scholar
• Sirichoat A, Krutsri S, Suwannakot K, et al. Melatonin protects against MTX-induced memory deficit and hippocampal neurogenesis impairment in a rat model. Biochem Pharmacol. 2019;163:225–233.
   PubMed Web of Science ®Google Scholar
• Naewla S, Sirichoat A, Pannangrong W, et al. Hesperidin alleviates MTX-induced memory deficits via hippocampal neurogenesis in adult rats. Nutrients. 2019;11(4):E936.
   PubMed Web of Science ®Google Scholar
• Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.
   PubMed Web of Science ®Google Scholar
• Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101(12):2842–2850.
   PubMed Web of Science ®Google Scholar
• Englander EW. DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions. DNA Repair (Amst). 2013;12(8):685–690.
   PubMed Web of Science ®Google Scholar
• Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40(7):872–882.
   PubMed Web of Science ®Google Scholar
• Ta LE, Espeset L, Podratz J, et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27(6):992–1002.
   PubMed Web of Science ®Google Scholar
• Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63(5):761–767.
   PubMed Web of Science ®Google Scholar
• Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409–422.
   PubMed Web of Science ®Google Scholar
• Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467–2498.
   PubMed Web of Science ®Google Scholar
• McDonald ES, Randon KR, Knight A, et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18(2):305–313.
   PubMed Web of Science ®Google Scholar
• Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70(1):18–25.
   PubMed Web of Science ®Google Scholar
• Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2011;2011:843019.
   PubMedGoogle Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584.
   PubMed Web of Science ®Google Scholar
• Gilardini A, Avila RL, Oggioni N, et al. Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2012;33(1):1–7.
   PubMed Web of Science ®Google Scholar
• Russell JW, Windebank AJ, McNiven MA, et al. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res. 1995;676(2):258–267.
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;31(3):CD005228
   Google Scholar
• Verschraegen C, Conrad CA, Hong WK. Subacute encephalopathic toxicity of cisplatin. Lung Canc. 1995;13(3):305–309.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Canc Manag Res. 2014;6:135–147.
   Web of Science ®Google Scholar
• Rybak LP, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear. 2019;40(2):197–204.
   PubMedGoogle Scholar
• Chirtes F, Albu S. Prevention and restoration of hearing loss associated with the use of cisplatin. BioMed Res Int. 2014;2014:925485.
   PubMed Web of Science ®Google Scholar
• Kaur T, Borse V, Sheth S, et al. Adenosine A1 receptor protects against cisplatin ototoxicity by suppressing the NOX3/STAT1 inflammatory pathway in the cochlea. J Neurosci. 2016;36(14):3962–3977.
   PubMed Web of Science ®Google Scholar
• Jamesdaniel S, Manohar S, Is HS. S-nitrosylation of cochlear proteins a critical factor in cisplatin-induced ototoxicity? Antioxid Redox Signal. 2012;17(7):929–933.
   PubMed Web of Science ®Google Scholar
• Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927–931.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–581.
   PubMed Web of Science ®Google Scholar
• Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum induced peripheral neuropathy. Pain. 2002;98(1–2):195–203.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12(12):1151–1161.
   PubMed Web of Science ®Google Scholar
• Khrunin A, Ivanova F, Moisseev A, et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2012;13(2):171–178.
   Google Scholar
• Kim HS, Kim MK, Chung HH, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264–269.
   PubMed Web of Science ®Google Scholar
• Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(Suppl 4):iv45–54.
   PubMed Web of Science ®Google Scholar
• Bigotte L, Arvidson B, Olsson Y. Cytofluorescence localization of adriamycin in the nervous system: distribution of the drug in the central nervous system adult mice after intravenous injection. Distribution of the drug in the central nervous system of normal adult mice after intravenous injection. Acta Neuropathol. 1982;57(2–3):121–129.
   PubMed Web of Science ®Google Scholar
• Bigotte L, Olsson Y. Toxic effects of adriamycin on the central nervous system. Ultrastructural changes in some circumventricular organs of the mouse after intravenous administration of the drug. Acta Neuropathol. 1983;61(3–4):291–299.
   PubMed Web of Science ®Google Scholar
• Tangpong J, Cole MP, Sultana R, et al. Adriamycin induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis. 2006;23(1):127–139.
   PubMed Web of Science ®Google Scholar
• Wang XM, Walitt B, Saligan L, et al. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015;72(1):86–96.
   PubMed Web of Science ®Google Scholar
• Pellacani C, Eleftheriou G. Neurotoxicity of antineoplastic drugs: mechanisms, susceptibility, and neuroprotective strategies. Adv Med Sci. 2020;65(2):265–285.
   PubMed Web of Science ®Google Scholar
• Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984 October;226(4673):466–468.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. [2014 February];124(2):617–630.
   PubMed Web of Science ®Google Scholar
• Wang EY, Biala AK, Gordon JW, et al. Autophagy in the heart: too much of a good thing? J Cardiovasc Pharmacol. 2012;60:110–117.
   PubMed Web of Science ®Google Scholar
• Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018 June;104(12):971–977.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–8852.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–4027.
   PubMed Web of Science ®Google Scholar
• Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Raphael MF, Caron HN, et al. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2014;4(9):CD006647.
   Google Scholar
• Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–961.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:10429.
   Web of Science ®Google Scholar
• Colombo A, Cipolla C, Beggiato M, et al. Cardiac toxicity of anticancer agents. Curr Cardiol Rep. 2013;15:362.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743.
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Schnabl KL, Marusak RA, et al. ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003;3(2):89–99.
   PubMedGoogle Scholar
• Hellmann K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without evidence. J Clin Oncol. 2007;25:4689–4690.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Orav EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without compelling evidence. J Clin Oncol. 2007;25:3179.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.
   PubMed Web of Science ®Google Scholar
• Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008;26:1106–1111.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011 June;2011(6):CD003917.
   Google Scholar
• Spalato Ceruso M, Napolitano A, Silletta M, et al. Use of cardioprotective dexrazoxane is associated with increased myelotoxicity in anthracycline-treated soft-tissue sarcoma patients. Chemotherapy. 2019;64(2):105–109.
   PubMed Web of Science ®Google Scholar
• Silvestris E, De Palma G, Canosa S, et al. Human ovarian cortex biobanking: A fascinating resource for fertility preservation in cancer. Int J Mol Sci. 2020;21:9.
   Web of Science ®Google Scholar
• Society AC. Cancer Facts & Figures 2013. Available online: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2013.html ( accessed on 2013 January 17).
   Google Scholar
• Longhi A, Pignotti E, Versari M, et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep. 2003;10:151–155.
   PubMed Web of Science ®Google Scholar
• Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25::292–296.
   PubMed Web of Science ®Google Scholar
• Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cisplatinum. Med Ped Oncol. 1989;17:409–413.
   PubMedGoogle Scholar
• Petersen PM, Hansen SW, Giwercman A, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol. 1994;5:355–358.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123–2125.
   PubMed Web of Science ®Google Scholar
• Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer.2008;50:347–351.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Meyer WH, Luo X, et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer. 1997;80:960–965.
   PubMed Web of Science ®Google Scholar
• Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: memorial Sloan-Kettering Cancer Center Experience. Cancer. 2002;95:1728–1734.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari C, Longhi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol. 2006;28:774–780.
   PubMed Web of Science ®Google Scholar
• Hendershot E, Volpe J, Taylor T, et al. Outpatient High-dose Methotrexate for Osteosarcoma: it’s Safe and Feasible, If You Want It. J Pediatr Hematol Oncol. [2019 July];41(5):394–398.
   PubMed Web of Science ®Google Scholar
• Edelmann MN, Daryani VM, Bishop MW, et al. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncol. [2016 February];2(2):201–208.
   PubMed Web of Science ®Google Scholar
• Serra M, Hattinger CM. The pharmacogenomics of osteosarcoma. Pharmacogenomics J. 2017 January;17(1):11–20.
   PubMed Web of Science ®Google Scholar
• Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 March;21(3):446–455.
   PubMed Web of Science ®Google Scholar
• Duffaud F, Mir O, Boudou-Rouquette P. et al. French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 January; 20(1):120–133.
   PubMed Web of Science ®Google Scholar
• Xu J, Guo W, Xie L. Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma? BMC Cancer. 2018;18(1):987.
   PubMedGoogle Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. [2012 February];23(2):508–516.
   PubMed Web of Science ®Google Scholar